This month marks a full year of my being under anti-PD1 treatment (MDX-1106 by Bristol Meyers Squibb) combined with vaccines at Moffitt in Tampa. However, anti-PD1 is now in development by 5 companies (BMS - MDX-1106, CureTech - CT-011, Merck/Scherring Plough - MK-3475/SCH 900475, Amplimmune/Glaxo Smith Kline - AMP-224, Genentec - no drug name yet). However, the Genentec drug is technically an anti-PD1 ligand. Trials for all of these include my BMS combo with vaccines at Moffitt as well as a new CureTech trial opening at Moffitt. CureTech is also opening trials at Yale, Dartmouth, and locations in New York, Boston, Europe, and Israel. Merck/Sherring Plough is opening sites in San Antonio, Houston, Los Angeles, San Francisco, and Toronto. Amplimmune will have sites in Detroit, North Carolina, and Nashville. BMS also has trials in New York and at Yale.
So far, BMS has been in the lead with trials already in process, but it looks like game on for the rest of them. Hope, they know what they are doing and there is real promise here. Usually pharma knows where to place it's bets....so we will see....as data remains hard to come by....more on that next.....
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment